These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18647228)

  • 1. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy.
    Savi P; Herault JP; Duchaussoy P; Millet L; Schaeffer P; Petitou M; Bono F; Herbert JM
    J Thromb Haemost; 2008 Oct; 6(10):1697-706. PubMed ID: 18647228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216.
    Carrie D; Caranobe C; Saivin S; Houin G; Petitou M; Lormeau JC; Van Boeckel C; Meuleman D; Boneu B
    Blood; 1994 Oct; 84(8):2571-7. PubMed ID: 7919374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antithrombotic activity of EP224283, a neutralizable dual factor Xa inhibitor/glycoprotein IIbIIIa antagonist, exceeds that of the coadministered parent compounds.
    Hechler B; Freund M; Alame G; Leguay C; Gaertner S; Cazenave JP; Petitou M; Gachet C
    J Pharmacol Exp Ther; 2011 Aug; 338(2):412-20. PubMed ID: 21527535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
    Petitou M; Nancy-Portebois V; Dubreucq G; Motte V; Meuleman D; de Kort M; van Boeckel CA; Vogel GM; Wisse JA
    Thromb Haemost; 2009 Nov; 102(5):804-10. PubMed ID: 19888512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity.
    Vogel GM; Meuleman DG; Van Dinther TG; Buijsman R; Princen AW; Smit MJ
    J Thromb Haemost; 2003 Sep; 1(9):1945-54. PubMed ID: 12941035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion.
    Paty I; Trellu M; Destors JM; Cortez P; Boëlle E; Sanderink G
    J Thromb Haemost; 2010 Apr; 8(4):722-9. PubMed ID: 20088937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization of EP217609, a new dual-action FIIa/FXa anticoagulant, by its specific antidote avidin: a phase I study.
    Gueret P; Combe S; Krezel C; Fuseau E; van Giersbergen PL; Petitou M; Neuhart E
    Eur J Clin Pharmacol; 2017 Jan; 73(1):15-28. PubMed ID: 27742998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa.
    Olson ST; Swanson R; Petitou M
    Blood; 2012 Mar; 119(10):2187-95. PubMed ID: 22144183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EP217609, a neutralisable dual-action FIIa/FXa anticoagulant, with antithrombotic effects in arterial thrombosis.
    Alame G; Mangin PH; Freund M; Riehl N; Magnenat S; Petitou M; Hechler B; Gachet C
    Thromb Haemost; 2015 Feb; 113(2):385-95. PubMed ID: 25374268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis.
    Trellu M; Fau JB; Cortez P; Cheng S; Paty I; Boëlle E; Donat F; Sanderink GJ
    Br J Clin Pharmacol; 2013 May; 75(5):1255-64. PubMed ID: 23078631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin.
    Herbert JM; Hérault JP; Bernat A; van Amsterdam RG; Vogel GM; Lormeau JC; Petitou M; Meuleman DG
    Circ Res; 1996 Sep; 79(3):590-600. PubMed ID: 8781492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of idraparinux and idrabiotaparinux for anticoagulant therapy.
    Harenberg J
    Thromb Haemost; 2009 Nov; 102(5):811-5. PubMed ID: 19888513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.
    Herbert JM; Hérault JP; Bernat A; van Amsterdam RG; Lormeau JC; Petitou M; van Boeckel C; Hoffmann P; Meuleman DG
    Blood; 1998 Jun; 91(11):4197-205. PubMed ID: 9596667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).
    Petitou M; Duchaussoy P; Jaurand G; Gourvenec F; Lederman I; Strassel JM; Bârzu T; Crépon B; Hérault JP; Lormeau JC; Bernat A; Herbert JM
    J Med Chem; 1997 May; 40(11):1600-7. PubMed ID: 9171870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short- and long-acting synthetic pentasaccharides.
    Koopman MM; Büller HR
    J Intern Med; 2003 Oct; 254(4):335-42. PubMed ID: 12974872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.
    Prandoni P; Tormene D; Perlati M; Brandolin B; Spiezia L
    Expert Opin Investig Drugs; 2008 May; 17(5):773-7. PubMed ID: 18447601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.
    Equinox Investigators
    J Thromb Haemost; 2011 Jan; 9(1):92-9. PubMed ID: 20946157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).
    Samama MM; Gerotziafas GT
    Thromb Res; 2003 Jan; 109(1):1-11. PubMed ID: 12679126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide.
    Meuleman DG; Hobbelen PM; Van Dinther TG; Vogel GM; Van Boeckel CA; Moelker HC
    Semin Thromb Hemost; 1991; 17 Suppl 1():112-7. PubMed ID: 2068564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.